Highlights from day 1 of the touchNEUROLOGY expert interviews filmed at EAN 2019 in Oslo, Norway, 30 June 2019.
Highlights from day 1 of the touchNEUROLOGY expert interviews filmed at EAN 2019 in Oslo, Norway, 30 June 2019.
Trending Topic
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the ...
Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors ...
Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.